Shin Kyung-Min, Park Ji-Eun, Yook Tae-Han, Kim Jong-Uk, Kwon Ojin, Choi Sun-Mi
Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, South Korea.
Future Medicine Division, Korea Institute of Oriental Medicine, Daejeon, South Korea.
Integr Med Res. 2019 Mar;8(1):1-7. doi: 10.1016/j.imr.2018.11.002. Epub 2018 Nov 24.
Prehypertension and hypertension are associated with cardiovascular disease, ischemic heart disease, and stroke morbidity. The purpose of this study is to evaluate the effectiveness and safety of moxibustion in patients with prehypertension or hypertension.
Forty-five subjects with prehypertension or stage I hypertension were randomized into three groups: moxibustion treatment group A (2 sessions/week for 4 weeks), moxibustion treatment group B (3 sessions/week for 4 weeks), and control group (nontreated group). The primary outcome measure was the change in blood pressure after 4 weeks of treatment. Safety was assessed at every visit.
There were no significant differences in systolic blood pressure (SBP) or diastolic blood pressure (DBP) among three groups after 4 weeks of treatment ( = 0.4798 and = 0.3252, respectively). In treatment group B, there was a significant decrease in SBP and DBP from baseline to 4 weeks of treatment (mean difference (MD) -9.55; = 0.0225, MD -7.55; = 0.0098, respectively). There were no significant differences among groups in secondary outcome measures after 4 weeks of treatment. Six adverse events (AEs) in the treatment group A and 12 AEs in the treatment group B occurred related to the moxibustion treatment.
In conclusion, the results of this study show that moxibustion (3 sessions/week for 4 weeks) might lower blood pressure in patients with prehypertension or stage I hypertension and treatment frequency might affect effectiveness of moxibustion in BP regulation. Further randomized controlled trials with a large sample size on prehypertension and hypertension should be conducted.
This study was registered with the 'Clinical Research Information Service (CRIS)', Republic of Korea (KCT0000469), and the protocol for this study was presented orally at the 15th International Council of Medical Acupuncture and Related Techniques (ICMART) in Athens, 25-27 May 2012.
高血压前期和高血压与心血管疾病、缺血性心脏病及中风发病率相关。本研究旨在评估艾灸对高血压前期或高血压患者的有效性和安全性。
45例高血压前期或Ⅰ期高血压患者被随机分为三组:艾灸治疗组A(每周2次,共4周)、艾灸治疗组B(每周3次,共4周)和对照组(未治疗组)。主要观察指标为治疗4周后的血压变化。每次就诊时评估安全性。
治疗4周后,三组的收缩压(SBP)和舒张压(DBP)均无显著差异(分别为P = 0.4798和P = 0.3252)。在治疗组B中,从基线到治疗4周时,SBP和DBP均显著下降(平均差值[MD]分别为-9.55;P = 0.0225,MD -7.55;P = 0.0098)。治疗4周后,次要观察指标在各组间无显著差异。治疗组A发生6例与艾灸治疗相关的不良事件(AE),治疗组B发生12例AE。
总之,本研究结果表明,艾灸(每周3次,共4周)可能降低高血压前期或Ⅰ期高血压患者的血压,治疗频率可能影响艾灸对血压调节的有效性。应开展关于高血压前期和高血压的进一步大样本随机对照试验。
本研究在大韩民国“临床研究信息服务(CRIS)”注册(KCT0000469),本研究方案于2012年5月25 - 27日在雅典举行的第15届国际医学针灸及相关技术理事会(ICMART)上进行了口头汇报。